Abstract:Clinical Trials, Ahead of Print. Background:Clinical trials are increasingly using Bayesian methods for their design and analysis. Inference in Bayesian trials typically uses simulation-based approaches such as Markov Chain Monte Carlo methods. Markov Chain Monte Carlo has high computational cost and can be complex to implement. The Integrated Nested Laplace Approximations algorithm provides approximate Bayesian inference without the need for computationally complex simulations, making it more efficient than Markov Chain Monte Carlo. The practical properties of Integrated Nested Laplace Approximations compared to Markov Chain Monte Carlo have not been considered for clinical trials. Using data from a published clinical trial, we aim to investigate whether Integrated Nested Laplace Approximations is a feasible and accurate alternative to Markov Chain Monte Carlo and provide practical guidance for trialists interested in Bayesian trial design.Methods:Data from an international Bayesian multi-platform adaptive trial that compared therapeutic-dose anticoagulation with heparin to usual care in non-critically ill patients hospitalized for COVID-19 were used to fit Bayesian hierarchical generalized mixed models. Integrated Nested Laplace Approximations was compared to two Markov Chain Monte Carlo algorithms, implemented in the software JAGS and stan, using packages available in the statistical software R. Seven outcomes were analysed: organ-support free days (an ordinal outcome), five binary outcomes related to survival and length of hospital stay, and a time-to-event outcome. The posterior distributions for the treatment and sex effects and the variances for the hierarchical effects of age, site and time period were obtained. We summarized these posteriors by calculating the mean, standard deviations and the 95% equitailed credible intervals and presenting the results graphically. The computation time for each algorithm was recorded.Results:The average overlap of the 95% credible interval for the treatment and sex effects estimated using Integrated Nested Laplace Approximations was 96% and 97.6% compared with stan, respectively. The graphical posterior densities for these effects overlapped for all three algorithms. The posterior mean for the variance of the hierarchical effects of age, site and time estimated using Integrated Nested Laplace Approximations are within the 95% credible interval estimated using Markov Chain Monte Carlo but the average overlap of the credible interval is lower, 77%, 85.6% and 91.3%, respectively, for Integrated Nested Laplace Approximations compared to stan. Integrated Nested Laplace Approximations and stan were easily implemented in clear, well-established packages in R, while JAGS required the direct specification of the model. Integrated Nested Laplace Approximations was between 85 and 269 times faster than stan and 26 and 1852 times faster than JAGS.Conclusion:Integrated Nested Laplace Approximations could reduce the computational complexity of Bayesian analysis in clinical trials as it is easy to implement in R, substantially faster than Markov Chain Monte Carlo methods implemented in JAGS and stan, and provides near identical approximations to the posterior distributions for the treatment effect. Integrated Nested Laplace Approximations was less accurate when estimating the posterior distribution for the variance of hierarchical effects, particularly for the proportional odds model, and future work should determine if the Integrated Nested Laplace Approximations algorithm can be adjusted to improve this estimation.

Predictive Probabilities Made Simple: A Fast and Accurate Method for Clinical Trial Decision Making

Estimating the Sampling Distribution of Posterior Decision Summaries in Bayesian Clinical Trials

A comparison of computational algorithms for the Bayesian analysis of clinical trials

From Pre-test and Post-test Probabilities to Medical Decision Making

Bayesian Prognostic Covariate Adjustment With Additive Mixture Priors

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation.

Simplification or simulation: Power calculation in clinical trials

Deep historical borrowing framework to prospectively and simultaneously synthesize control information in confirmatory clinical trials with multiple endpoints

Optimal Bayesian predictive probability for delayed response in single-arm clinical trials with binary efficacy outcome

Decision-making with multiple correlated binary outcomes in clinical trials

Bayesian Interim Analysis and Efficiency of Phase III Randomized Trials

Uncertainty Quantification and Interpretability for Clinical Trial Approval Prediction

Combining Model-Based Clinical Trial Simulation, Pharmacoeconomics, and Value of Information to Optimize Trial Design

Towards Treatment Effect Interpretability: A Bayesian Re-analysis of 194,129 Patient Outcomes Across 230 Oncology Trials

The Predictive Individual Effect for Survival Data

Sample size re-estimation in a superiority clinical trial using a hybrid classical and Bayesian procedure

Optimality of testing procedures for survival data

Strategies for power calculations in predictive biomarker studies in survival data

Eliciting the Discount Parameter in a Power Prior Method on the Basis of the Type I Error Consideration